Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
NCT04611126 · Inge Marie Svane · PHASE1/PHASE2 · terminated · last registry update 2025-08-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment” | – | Registry record, Inge Marie Svane |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CTLA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-11Results posted on the registry: Agenus Inc., Zalifrelimab + Balstilimab (NCT03495882)
- 2026-08-04Results posted on the registry: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2026-08-04Also stopped (terminated): Academic and Community Cancer Research United, Ipilimumab + Nivolumab (NCT05199285)
- 2026-07-22Phase 3 first posted: AstraZeneca, Dato-DXd + Rilvegostomig (NCT07720284)
- 2026-07-16Also stopped (terminated): Dana-Farber Cancer Institute, Ipilimumab + Nivolumab (NCT03425331)
- 2026-07-14Phase 3 first posted: Akeso, Cadonilimab + CAPOX regimen (NCT07700979)
- 2026-07-02Results posted on the registry: Diwakar Davar, Vidutolimod (CMP-001) + Nivolumab (NCT04401995)
- 2026-06-29Results posted on the registry: Imperial College London, Ipilimumab + Nivolumab (NCT03682276)
- 2026-06-23Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab/Quavonlimab + Lenvatinib (NCT04740307)
- 2026-06-11Phase 3 first posted: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., tegafur, Gimeracil and Oteracil Potassium Capsules + Sintilimab Placebo (NCT07643623)
- 2026-06-10Also stopped (withdrawn): National Cancer Institute (NCI), Ipilimumab + Nivolumab (NCT04500548)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Pembrolizumab/Quavonlimab (NCT04895722)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Favezelimab (NCT03516981)
- 2026-06-03Results posted on the registry: University of Wisconsin, Madison, hu14.18-IL2 + Nivolumab (NCT03958383)
- 2026-06-03Also stopped (terminated): University of Wisconsin, Madison, hu14.18-IL2 + Nivolumab (NCT03958383)
- 2026-05-29Results posted on the registry: NewLink Genetics Corporation, Indoximod + Ipilimumab (NCT02073123)
- 2026-05-26Also stopped (terminated): ImmunityBio, Inc., NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab (NCT03520686)
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-05-05Results posted on the registry: Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-05-05Also stopped (terminated): Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-04-30Also stopped (terminated): M.D. Anderson Cancer Center, Ipilimumab + Nivolumab (NCT03799445)
- 2026-04-29Results posted on the registry: Regeneron Pharmaceuticals, REGN2810 + REGN2810/chemo/ipi (NCT03409614)
- 2026-04-23Also stopped (terminated): Emory University, Ipilimumab + Nivolumab (NCT05341349)
- 2026-04-21Also stopped (terminated): Incyte Corporation, Epacadostat + ipilimumab (NCT01604889)
- 2026-04-20Also stopped (terminated): Servier Bio-Innovation LLC, Ivosidenib + Nivolumab (NCT05921760)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision